Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: A case series

被引：3

作者：

Serratrice C. ^{[1
]}

Swiader L. ^{[2
]}

Serratrice J. ^{[2
]}

机构：

[1] Department of Internal Medicine, Foundation Hospital Saint Joseph, 26 Boulevard de Louvain, Marseille

[2] Department of Internal Medicine, CHU Timone, Marseille

来源：

Journal of Medical Case Reports | / 9卷 / 1期

关键词：

Gaucher disease; Imiglucerase; Miglustat;

D O I：

10.1186/s13256-015-0617-5

中图分类号：

学科分类号：

摘要：

Introduction: Gaucher disease is caused by a deficiency of the enzyme β-glucocerebrosidase. Treatment with enzyme replacement therapy has been available for the past two decades but, although effective, enzyme replacement therapy can be delivered only by intravenous infusion every other week. The oral substrate reduction therapy miglustat (Zavesca®) has been available in Europe since 2002 for the treatment of patients with mild or moderate Gaucher disease type 1 for whom enzyme replacement therapy is unsuitable or not a therapeutic option. There are few published real-world data on the use of miglustat as a maintenance therapy in Gaucher disease type 1 patients switched from previous enzyme replacement therapy. We report a case series of three patients who were switched from long-term enzyme replacement therapy to miglustat for various reasons. Case presentation: All three patients were Caucasian and had confirmed Gaucher disease type 1. An 80-year-old man requested a switch to oral miglustat therapy in preference to ongoing intravenous enzyme replacement therapy, a 57-year-old woman was commenced on miglustat due to a shortage of imiglucerase, and a 56-year-old woman was switched from previous enzyme replacement therapy due to allergic reactions to intravenous infusions. Hematological disease parameters were stable in each patient on previous enzyme replacement therapy. Two patients continue to be treated with miglustat, having shown good tolerability and stable core disease parameters for approximately 4 years. One patient, who was also stable during 7 years of therapy, eventually discontinued miglustat as a precaution because he developed peripheral neuropathy of as yet unknown origin. Conclusions: Overall, our experience indicates that miglustat can be used as maintenance therapy for Gaucher disease type 1 after initial enzyme replacement therapy, but the selection of patients to whom this approach should be applied should be made after careful consideration of all disease parameters. © 2015 Serratrice et al.

引用

共 15 条

[1]

Cox T.M., Schofield J.P., Gaucher's disease: Clinical features and natural history, Baillieres Clin Haematol, 10, pp. 657-689, (1997)

[2]

Charrow J., Andersson H.C., Kaplan P., Kolodny E.H., Mistry P., Pastores G., Et al., The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease, Arch Intern Med, 160, pp. 2835-2843, (2000)

[3]

Elstein D., Zimran A., Review of the safety and efficacy of imiglucerase treatment of Gaucher disease, Biologics, 3, pp. 407-417, (2009)

[4]

Andersson H., Kaplan P., Kacena K., Yee J., Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1, Pediatrics, 122, pp. 1182-1190, (2008)

[5]

Cox T., Lachmann R., Hollak C., Aerts J., Van Weely S., Hrebicek M., Et al., Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis, Lancet, 355, pp. 1481-1485, (2000)

[6]

Heitner R., Elstein D., Aerts J., Weely S., Zimran A., Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease, Blood Cells Mol Dis, 28, pp. 127-133, (2002)

[7]

Elstein D., Hollak C., Aerts J.M., Van Weely S., Maas M., Cox T.M., Et al., Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease, J Inherit Metab Dis, 27, pp. 757-766, (2004)

[8]

Pastores G.M., Elstein D., Hrebicek M., Zimran A., Effect of miglustat on bone disease in adults with type 1 Gaucher disease: A pooled analysis of three multinational, open-label studies, Clin Ther, 29, pp. 1645-1654, (2007)

[9]

Hollak C.E., Vom Dahl S., Aerts J.M., Belmatoug N., Bembi B., Cohen Y., Et al., Force majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease, Blood Cells Mol Dis, 44, pp. 41-47, (2010)

[10]

Giraldo P., Alfonso P., Atutxa K., Fernandez-Galan M.A., Barez A., Franco R., Et al., Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: The ZAGAL project, Haematologica, 94, pp. 1771-1775, (2009)

← 1 2 →